Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

Fig. 7

Dose response curve obtained from growth inhibition with EG22 in a panel of Chinese Hamster Lung cancer cell lines. V79 cells express wild type BRCA2.The VC8 cell line expresses mutant BRCA2, and VC8-BRCA is transfected with the wild type BRCA2 gene. EG22 was significantly more potent against the BCRA2 mutant cell line (p < 0.0001). ZSM02 did not show significant selectivity for VC8 when compared with V79. However, a 3-fold selectivity (p < 0.001) was apparent when compared with its isogenic VC8-BRCA counterpart. *** p < 0.001, ****p < 0.0001, ns. Not Significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us